Promise of Cannabis-Based Medicine in Healthcare and the Path to Get There, New Webinar Hosted by Xtalks
TORONTO (PRWEB) July 09, 2019 -- The live webinar upcoming on Tuesday, July 30, 2019 at 11am EDT (4pm BST/UK) will provide a roadmap for developing cannabinoids into medicines, including:
- Historical overview of role of cannabis and cannabinoids in medicine
- The most promising indications for cannabinoid medicines
- Recent advances in medicinal cannabis science
- Most pressing research priorities in cannabis medicine development
- The barriers to conducting cannabinoid research and how to navigate the regulatory and legal requirements
- Interpreting study results and how they influence development strategy and potential postmarketing requirements
Recent changes in federal and state regulation of cannabis and cannabis-derived substances have renewed interest and scrutiny into its potential as a medicine. As states continue to allow for use of cannabis and cannabis products, preliminary studies and anecdotal evidence suggest that patients are turning to these products to treat a variety of disorders, including pain, post-traumatic stress disorder (PTSD), epilepsy and depression. Despite this growing adoption, the vast majority of these products have not been thoroughly evaluated. There is still much that is unknown about the safety and efficacy of these products, including effects of long-term use, potential drug-drug interactions, effects on fetal development and more.
US Food and Drug Administration (FDA) approval for these products will require that these questions be answered, though conducting this research can appear to be an overwhelming barrier for sponsors, particularly as cannabis remains a Schedule I substance on the federal level. This webinar will outline a path for the development of cannabis-based medicine, including barriers to research and how to navigate them, necessary studies required for FDA approval and how results from these studies can impact drug scheduling and risk management and surveillance requirements post-approval.
Featured speakers for this free session include Sidney H. Schnoll, MD, PhD, Vice President of Pharmaceutical Risk Management Services at PinneyAssociates, Jack E. Henningfield, PhD, Vice President of Research, Health Policy, and Abuse Liability at PinneyAssociates, and Marilyn A. Huestis, PhD, President of Huestis & Smith Toxicology, LLC.
For more information visit: Promise of Cannabis-Based Medicine in Healthcare and the Path to Get There.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Candice Tang, Xtalks, http://www.xtalks.com, 1 (416) 977-6555, [email protected]
Share this article